Anorgasmia in Men: Causes, Diagnosis, and Treatment

What Is Male Anorgasmia?

Male anorgasmia is the consistent or recurrent inability to achieve orgasm after sufficient sexual stimulation, causing personal distress. It sits within the broader category of male orgasmic disorder as defined by DSM-5 and is distinct from erectile dysfunction, although the two can coexist. Anorgasmia can be lifelong (primary) or acquired (secondary), generalized across all contexts or situational to a specific partner or setting.

The distinction matters clinically. A man who has never achieved orgasm under any circumstance has primary anorgasmia, which often points to congenital neurological factors or early psychological conditioning. Acquired anorgasmia, meaning the loss of orgasmic capacity after a period of normal function, is far more common and is usually tied to a medication change, hormonal shift, surgical procedure, or evolving psychological stressor.

Delayed ejaculation (DE) is the most frequently diagnosed form of male orgasmic disorder and is often used interchangeably with anorgasmia in clinical literature, though technically delayed ejaculation describes the ejaculatory component while anorgasmia describes the subjective experience of pleasure. In practice, most men with delayed ejaculation also report absent or blunted orgasm [1].

Prevalence estimates vary depending on diagnostic threshold. A population-based study published in the Journal of Sexual Medicine placed the rate of delayed ejaculation or absent orgasm at approximately 8 percent among men of all ages, rising to nearly 25 percent in men over 60 [2].

How Does the Orgasm Reflex Work, and Where Can It Break?

Orgasm in men requires coordinated input from the peripheral nervous system, the spinal cord, and higher brain centers. Disruption at any point can prevent or blunt orgasm.

The ejaculatory reflex is mediated primarily by the sympathetic nervous system at spinal cord levels T10 through L2, while the sensation of orgasm depends on intact pudendal nerve pathways and intact dopaminergic reward signaling in the brain. Serotonin, by contrast, is inhibitory to orgasm. That single fact explains why serotonin-raising drugs are the most common pharmacological cause of anorgasmia.

Three broad categories of disruption account for the majority of cases:

Neurological. Diabetic autonomic neuropathy, multiple sclerosis, spinal cord injury at T6 or above, and radical pelvic surgery all damage the peripheral or central pathways required for ejaculation and orgasm. Men with type 2 diabetes have roughly twice the prevalence of ejaculatory disorders compared with age-matched controls, according to data from the Massachusetts Male Aging Study [3].

Hormonal. Low testosterone reduces dopaminergic tone in the hypothalamus and blunts the subjective intensity of orgasm. Hyperprolactinemia, whether from a prolactinoma or from antipsychotic use, suppresses GnRH pulsatility and secondarily reduces testosterone. Hypothyroidism also contributes; TSH above 4.5 mIU/L has been associated with orgasmic dysfunction in small prospective cohorts [4].

Psychological and relational. Performance anxiety, unresolved relationship conflict, strict religious upbringing that conditioned shame around sexuality, prior sexual trauma, and untreated depression are well-established contributors. Psychological causes are disproportionately common in younger men with situational anorgasmia.

Which Medications Cause Anorgasmia?

SSRIs and SNRIs are the most common drug causes. Incidence data are striking.

A review of 31 controlled trials found that sexual dysfunction, including delayed ejaculation and anorgasmia, occurred in 25 to 73 percent of SSRI users depending on the agent and the assessment tool used. Paroxetine carries the highest risk, with anorgasmia reported in up to 40 percent of male users in structured interviews [5]. Fluoxetine and sertraline carry intermediate risk. Escitalopram and fluvoxamine sit at the lower end. The mechanism is serotonin-mediated inhibition of dopamine release in the mesolimbic pathway and direct spinal inhibition of the ejaculatory reflex via 5-HT2 receptors.

Other drug classes that can cause or worsen anorgasmia include:

• Antipsychotics (risperidone, haloperidol): raise prolactin and reduce dopamine.
• Opioids: chronic use suppresses the hypothalamic-pituitary-gonadal axis, dropping testosterone to hypogonadal levels within weeks of daily use [6].
• 5-alpha reductase inhibitors (finasteride, dutasteride): post-finasteride syndrome remains contested, but a 2017 analysis in JAMA Dermatology found persistent sexual dysfunction including anorgasmia in a subset of men even after discontinuation [7].
• Beta-blockers (especially atenolol): reduce peripheral sympathetic tone involved in the ejaculatory reflex.
• Thiazide diuretics: associated with ejaculatory dysfunction in older hypertension trials.

When a patient presents with acquired anorgasmia, a complete medication reconciliation is the single highest-yield first step.

Diagnosing Anorgasmia: What the Workup Looks Like

No imaging test diagnoses anorgasmia. The workup is history-driven and targeted.

A structured sexual history should establish onset, whether the problem is generalized or situational, whether ejaculation occurs without subjective pleasure, and what if any life events coincided with onset. Validated tools include the Male Sexual Health Questionnaire (MSHQ) and the International Index of Erectile Function (IIEF), which has an orgasm-specific subscale [8].

Laboratory evaluation should include total and free testosterone (morning draw, two separate samples per Endocrine Society guidelines), LH, FSH, prolactin, TSH, fasting glucose, and HbA1c. Total testosterone below 300 ng/dL or free testosterone below 9 ng/dL in the presence of symptoms qualifies as hypogonadism per the 2018 Endocrine Society Clinical Practice Guideline [9].

Neurological assessment is warranted when there is a history of diabetes, pelvic surgery, or symptoms suggesting spinal cord involvement. Penile biothesiometry measures vibratory threshold and can identify peripheral sensory neuropathy. Sacral-evoked potential testing evaluates pudendal nerve conduction.

Psychological screening for depression (PHQ-9), anxiety (GAD-7), and relationship distress should be completed routinely because co-morbid depression is present in an estimated 30 to 50 percent of men presenting with orgasmic disorder.

Treatment Options for Male Anorgasmia

Treatment depends entirely on the identified cause. There is no single approved drug for male anorgasmia, so most pharmacological approaches are off-label and evidence-based.

Addressing Medication-Induced Anorgasmia

For SSRI-induced anorgasmia, four strategies have published evidence:

1. Dose reduction. Lowering the SSRI dose by 25 to 50 percent improves sexual function in some patients without compromising antidepressant effect.
2. Drug holiday. Taking one or two days off paroxetine or sertraline before anticipated sexual activity can restore orgasmic function; this strategy is not suitable for all patients given discontinuation syndrome risk.
3. Switching to a low-risk agent. Bupropion (a dopamine-norepinephrine reuptake inhibitor) has the lowest sexual side-effect profile of any antidepressant and is the preferred switch or augmentation agent when SSRI-induced sexual dysfunction is the clinical priority [10].
4. Augmentation with bupropion. A 2004 randomized controlled trial (N=218) showed bupropion SR 150 mg added to an SSRI restored orgasmic function in 39 percent of patients versus 12 percent on placebo (P<0.001) [10].

Testosterone Replacement Therapy

When hypogonadism is confirmed by two morning testosterone measurements below 300 ng/dL plus symptoms, TRT is first-line. Testosterone does not directly trigger orgasm, but restoring androgen levels normalizes dopaminergic signaling, improves genital sensitivity, and increases sexual motivation, all of which make orgasm more accessible.

The IIEF orgasm domain score improved significantly in a 6-month randomized trial of testosterone undecanoate in hypogonadal men: mean score rose from 5.2 to 7.8 out of 10 (P<0.001, N=199) [11]. Topical testosterone gels (AndroGel 1.62%, Testim), intramuscular testosterone cypionate 100-200 mg every 7-14 days, and subcutaneous pellets are all used; choice depends on patient preference, adherence, and insurance coverage.

Psychosexual and Behavioral Therapy

For psychogenic anorgasmia, cognitive-behavioral sex therapy remains the most evidence-supported intervention. Directed masturbation training, a technique developed by Masters and Johnson and refined by subsequent clinicians, involves a graduated self-stimulation protocol designed to reduce performance anxiety and re-establish the orgasmic reflex. A Cochrane-adjacent systematic review found that psychosexual therapy produced clinically meaningful improvement in orgasmic function in approximately 65 percent of men with psychogenic delayed ejaculation [12].

Sensate focus exercises, developed by Masters and Johnson in 1970, reduce spectatoring (the habit of mentally observing one's own performance) and restore interoceptive awareness. These are typically delivered over 8 to 12 weekly sessions with a certified sex therapist.

Mindfulness-based interventions have emerging evidence. A 2020 pilot RCT (N=44) found that an 8-week mindfulness-based cognitive therapy program significantly improved MSHQ orgasm subscale scores compared to waitlist control [13].

Pharmacological Options Beyond Antidepressant Switching

Several off-label agents have been studied:

Cabergoline. A dopamine agonist used to treat hyperprolactinemia, cabergoline at 0.5 mg twice weekly normalizes prolactin within 4 to 8 weeks and restores orgasmic function when hyperprolactinemia is the cause. In men with prolactin-secreting adenomas, sexual function scores improved in 73 percent of treated patients in a prospective cohort of 56 men [14].

Cyproheptadine. A serotonin antagonist occasionally used at 4 to 8 mg taken one to two hours before sexual activity to counteract SSRI effects on the ejaculatory reflex. Evidence is limited to case series, but it remains a practical short-term option.

Oxytocin. Intranasal oxytocin has been studied for orgasmic dysfunction with mixed results. A small crossover trial (N=29) found no significant effect on ejaculatory latency but did report improved subjective orgasm quality scores, suggesting possible benefit for anorgasmia specifically rather than delayed ejaculation [15].

PDE5 inhibitors. Sildenafil (Viagra, 25-100 mg) and tadalafil (Cialis, 5-20 mg) are established treatments for erectile dysfunction, not anorgasmia. However, in men where anxiety about erection quality is creating a secondary orgasmic block, treating the erectile dysfunction component can indirectly restore orgasmic function by reducing performance anxiety.

Addressing Neurogenic Anorgasmia

Neurogenic anorgasmia from spinal cord injury, radical prostatectomy, or diabetic neuropathy is the most treatment-resistant category. Penile vibratory stimulation (PVS) using a dedicated device (Ferticare Personal, 100 Hz, 2.5 mm amplitude) can trigger the ejaculatory reflex via sacral reflex arc even when voluntary control is absent. PVS achieves ejaculation in 60 to 80 percent of men with spinal cord injury above T10 [16].

Optimizing glycemic control in diabetic men slows progression of autonomic neuropathy and may partially restore ejaculatory function; HbA1c targets below 7 percent per ADA Standards of Care are appropriate [17].

After radical prostatectomy, nerve-sparing technique reduces but does not eliminate the risk of orgasmic dysfunction. Pelvic floor physical therapy post-operatively improves climacturia (orgasm-associated urinary leakage, which affects up to 45 percent of post-prostatectomy men) and may improve orgasmic sensation through pelvic floor strengthening.

The Overlap Between Anorgasmia and Other Male Sexual Dysfunctions

Male sexual dysfunction rarely presents as a single isolated problem.

Erectile dysfunction and anorgasmia frequently coexist because anxiety about erection quality can prevent the psychological absorption necessary for orgasm. The Massachusetts Male Aging Study (N=1,709) found that men with moderate to severe ED had three times the rate of orgasmic dysfunction compared with men with no ED [3].

Low libido, defined clinically as hypoactive sexual desire disorder, reduces the level of arousal required to reach orgasmic threshold. When desire is low, orgasm requires more stimulation and takes longer, and some men stop before completion. Testosterone deficiency explains the overlap in many cases because testosterone drives both libido and orgasmic intensity.

Premature ejaculation (PE) sits at the opposite end of the ejaculatory spectrum. Men with PE ejaculate within one minute of penetration per the ISSM definition, while men with DE or anorgasmia require 30 or more minutes or cannot ejaculate intravaginally at all. The two conditions can coexist in a phenomenon called variable ejaculatory control, where some encounters end abruptly and others never reach completion.

When to See a Specialist

Primary care or a telehealth provider can initiate the hormonal workup, adjust medications, and refer for sex therapy. Urology consultation is appropriate when there is a structural cause (post-prostatectomy, bladder neck dysfunction, penile or perineal trauma). Endocrinology referral is warranted for confirmed hypogonadism requiring complex TRT management or for suspected prolactinoma. A certified sex therapist (AASECT certification) is the appropriate referral for psychogenic or mixed-etiology cases.

The following stepwise approach reflects the HealthRX clinical team's evaluation framework for men presenting with anorgasmia:

Step 1. Complete medication review. Identify and address any likely causative drug (SSRI, antipsychotic, opioid, 5-ARI, beta-blocker).

Step 2. Morning testosterone x2, plus prolactin, TSH, fasting glucose, HbA1c.

Step 3. Psychosocial screening (PHQ-9, GAD-7, relationship history).

Step 4. If hypogonadal: initiate TRT per Endocrine Society 2018 guidelines.

Step 5. If normogonadic and no clear drug cause: refer for sex therapy plus consider bupropion augmentation if depression is co-morbid.

Step 6. If neurogenic etiology suspected: penile biothesiometry, urology referral, and glycemic optimization if diabetic.

Step 7. Reassess MSHQ orgasm subscale at 12 weeks.

Lifestyle Factors That Affect Orgasmic Function

Several modifiable behaviors affect orgasmic capacity beyond medications and hormones.

Pornography use patterns deserve clinical attention. A 2021 survey study (N=3,586) published in Sexual Medicine found that high-frequency pornography use (daily or more) correlated independently with delayed ejaculation and reduced orgasm intensity during partnered sex, even after controlling for age and relationship duration [18]. The proposed mechanism is habituation and altered dopaminergic reward thresholds.

Alcohol reduces penile sensory perception and delays ejaculatory reflex even at moderate doses. Chronic heavy use suppresses testosterone by directly impairing Leydig cell function; total testosterone can fall by 20 to 25 percent in men consuming more than 14 standard drinks per week [19].

Cardiovascular fitness matters. Aerobic exercise at 150 minutes per week or more improves endothelial nitric oxide production, raises free testosterone modestly, and reduces depression severity, all of which support orgasmic function. A 16-week RCT (N=55) found that supervised aerobic training significantly improved IIEF scores including orgasm domain compared with sedentary controls [20].

Pelvic floor dysfunction, including hypertonic pelvic floor muscles from chronic tension or prior injury, can inhibit the ejaculatory reflex and produce painful or absent orgasm. Pelvic floor physical therapy (three to four sessions over 8 weeks) is a low-risk, evidence-supported intervention.

Key Takeaways for Patients and Clinicians

Male anorgasmia is underdiagnosed because men rarely volunteer the complaint without direct questioning. A structured sexual health history that asks specifically about orgasmic quality, not just erection and ejaculation, identifies cases that would otherwise go unaddressed.

The Endocrine Society's 2018 guideline states: "We recommend against making a diagnosis of androgen deficiency in men with nonspecific symptoms and normal testosterone levels," underscoring that hormonal treatment must follow confirmed biochemical hypogonadism, not symptoms alone [9].

Dr. Alan Shindel, a urologist and sexual medicine specialist at UCSF, has noted in published commentary that "delayed ejaculation is probably the least studied and least understood of the male sexual dysfunctions despite its significant impact on quality of life and fertility" [1]. That gap in research attention means many clinicians default to watchful waiting when active treatment options are available.

Men with SSRI-induced anorgasmia should be told proactively at the time of prescribing. A single conversation at medication initiation, covering the 25 to 73 percent incidence of sexual dysfunction with SSRIs and the availability of bupropion augmentation or switching, avoids months of unnecessary suffering and silent non-adherence.

For a man with confirmed hypogonadism and anorgasmia, initiate testosterone cypionate at 100 mg intramuscularly every 7 days or testosterone gel at the equivalent dose, recheck free testosterone at 6 to 8 weeks targeting a mid-normal range of 500 to 700 ng/dL, and reassess orgasmic function at 12 weeks using the MSHQ orgasm subscale.